TAIPEI, Taiwan, April 19, 2019 /PRNewswire/ -- ACTmed, a joint
venture between Canon Medical Systems Corporation (Headquarters:
Otawara, Tochigi Prefecture, Japan; President and CEO: Toshio Takiguchi), and ACT Genomics
(Headquarters: Taipei, Taiwan,
CEO: Hua Chien Chen) has established an analysis laboratory named
"Shonan iPark Laboratory" in "Shonan Health Innovation Park". With
the laboratory, ACTmed will offer precision cancer medicine to
fulfill the clinical needs and drug development activities in
Japan, making it possible to
provide comprehensive services to quickly address requests from
clients and promptly respond to their inquiries. Full-scale
operation is scheduled to commence in July
2019.
ACT Genomics will continue to provide medical informatics
solution through its AI-powered bioinformatics pipelines to ACTmed,
which enable the joint venture to provide medical interpretation
that is created based on clinical databases of genetic information
specifically for Asian populations as well as other clinical
information curated from available database. "We are excited to see
the launch and to facilitate precision medicine service for
biomarker-driven clinical trials in oncology and treatment
identification for cancer patients in Japan," said
Dr. Hua Chien Chen at ACT
Genomics.
In addition to the NGS-lab launched in Japan, ACT Genomics expects to open another
new lab in Hong Kong in
June 2019, to continue the expansion
and focus on Asia market. As the
only Asian diagnostic company in the US Friends of Cancer
Research-led TMB harmonization project, ACT Genomics has developed
proprietary computational algorithm for Tumor Mutational Burden
(TMB) calculation with tissue-based ACTOnco® to support increasing
demands from both clinical research and diagnostic activities in
most of the major Asian cities in Japan, China,
Taiwan, Hong Kong, Singapore and South
East Asia countries and
regions.
About ACTG
Founded in 2014, ACTG provides optimal cancer treatment plan,
cancer relapse and drug resistance monitoring as well as cancer
risk assessment and immunotherapy evaluation. The company achieves
precise cancer genetic variants detection with minimum tumor
samples, and delivers to every cancer patient personalized genomic
information based-treatment plans through cutting-edge NGS
platform, medical report and integrated services. The company also
provides comprehensive data analysis on cancer genomics applying
Artificial Intelligence and integrates genomic databases
information with Asia specific
genome profiling.
ACTG's comprehensive portfolio received the 2017 Asia Pacific
Molecular Diagnostics Product Line Strategy Leadership Award by
Frost & Sullivan.
Media contact:
ACT Genomics
Victor Chan
Chief Finance Officer
Email: victorchan@actgenomics.com
Angus Wu
Director, Business Development
Email: anguswu@actgenomics.com
View original
content:http://www.prnewswire.com/news-releases/act-genomics-establishes-ngs-laboratory-to-offer-comprehensive-cancer-genomic-profiling-service-in-japan-300834581.html
SOURCE ACT Genomics